Add to balance / Manage account | User: | Log out |
Prospect News home > News index > List of issuers A > Headlines for Athenex, Inc. > News item |
Athenex closes $14.67 million pharmaceutical asset sale to Oaktree
By Sarah Lizee
Olympia, Wash., Aug. 9 – Athenex, Inc. closed the sale of some of its pharmaceutical division assets to Oaktree Strategic Credit Asset Holdings, LLC and Oaktree fund Administration, LLC, according to a notice filed Tuesday with the U.S. Bankruptcy Court for the Southern District of Texas.
The sale closed on July 28.
The final purchase price after considering adjustments under the asset purchase agreement is $14.67 million.
Pending the closing, the debtors continued to receive collections of accounts receivable.
Athenex is a clinical-stage biopharmaceutical company with headquarters in Buffalo, N.Y. The company filed bankruptcy on May 14 under Chapter 11 case number 23-90295.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.